TASIGNA 150mg (nilotinib)
₨ 125,400
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Related Products
Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early
breast cancer.
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Reviews
There are no reviews yet.